187 related articles for article (PubMed ID: 23233711)
21. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
[No Abstract] [Full Text] [Related]
22. Inoperable bulky melanoma responds to neoadjuvant therapy with vemurafenib.
Fadaki N; Cardona-Huerta S; Martineau L; Thummala S; Cheng ST; Bunker SR; Garcia-Kennedy R; Wang W; Minor D; Kashani-Sabet M; Leong SP
BMJ Case Rep; 2012 Oct; 2012():. PubMed ID: 23093505
[TBL] [Abstract][Full Text] [Related]
23. Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma.
Wolf SE; Meenken C; Moll AC; Haanen JB; van der Heijden MS
BMC Cancer; 2013 Dec; 13():561. PubMed ID: 24289205
[TBL] [Abstract][Full Text] [Related]
24. [New hope in metastatic melanoma treatment?].
Guillot B
Ann Dermatol Venereol; 2012 Oct; 139(10):693-4. PubMed ID: 23122388
[No Abstract] [Full Text] [Related]
25. Complete pathologic response after neoadjuvant treatment with vemurafenib for malignant melanoma.
Kaidar-Person O; Eran A; Bar-Sela G
J Am Acad Dermatol; 2014 Feb; 70(2):e39-41. PubMed ID: 24438978
[No Abstract] [Full Text] [Related]
26. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
Seeley AR; De Los Santos JF; Conry RM
Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
[TBL] [Abstract][Full Text] [Related]
27. The role of radiotherapy in the overall treatment of melanoma.
Forschner A; Heinrich V; Pflugfelder A; Meier F; Garbe C
Clin Dermatol; 2013; 31(3):282-9. PubMed ID: 23608447
[TBL] [Abstract][Full Text] [Related]
28. Vemurafenib: in unresectable or metastatic melanoma.
Keating GM
BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
[TBL] [Abstract][Full Text] [Related]
29. Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption.
Braunstein I; Gangadhar TC; Elenitsas R; Chu EY
J Cutan Pathol; 2014 Jun; 41(6):539-43. PubMed ID: 24517243
[TBL] [Abstract][Full Text] [Related]
30. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
31. Vemurafenib beyond progression in a patient with metastatic melanoma: a case report.
Grimaldi AM; Simeone E; Palla M; Festino L; Caracò C; Mozzillo N; Petrillo A; Muto P; Ascierto PA
Anticancer Drugs; 2015 Apr; 26(4):464-8. PubMed ID: 25622086
[TBL] [Abstract][Full Text] [Related]
32. Efflorescence of scalp cysts during vemurafenib treatment following brain radiation therapy: a radiation recall dermatitis?
Reigneau M; Granel-Brocard F; Geoffrois L; Bauman AS; Tréchot P; Barbaud A; Schmutz JL
Eur J Dermatol; 2013; 23(4):544-5. PubMed ID: 24001519
[No Abstract] [Full Text] [Related]
33. Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report.
Lee JM; Mehta UN; Dsouza LH; Guadagnolo BA; Sanders DL; Kim KB
Melanoma Res; 2013 Apr; 23(2):175-8. PubMed ID: 23358426
[TBL] [Abstract][Full Text] [Related]
34. Complete regression of a previously untreated melanoma brain metastasis with ipilimumab.
Schartz NE; Farges C; Madelaine I; Bruzzoni H; Calvo F; Hoos A; Lebbé C
Melanoma Res; 2010 Jun; 20(3):247-50. PubMed ID: 20216240
[TBL] [Abstract][Full Text] [Related]
35. Altered Morphology and Immunohistochemical Characteristics in Metastatic Malignant Melanoma After Therapy With Vemurafenib.
Powell MR; Sheehan DJ; Kleven DT
Am J Dermatopathol; 2016 Sep; 38(9):e137-9. PubMed ID: 27541173
[TBL] [Abstract][Full Text] [Related]
36. S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma.
Abusaif S; Jradi Z; Held L; Pflugfelder A; Weide B; Meier F; Garbe C; Eigentler TK
Melanoma Res; 2013 Oct; 23(5):396-401. PubMed ID: 23907232
[TBL] [Abstract][Full Text] [Related]
37. Spatial intra-tumour heterogeneity in acquired resistance to targeted therapy complicates the use of PDX models for co-clinical cancer studies.
Wellbrock C
EMBO Mol Med; 2015 Sep; 7(9):1087-9. PubMed ID: 26174485
[TBL] [Abstract][Full Text] [Related]
38. Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib.
Starz H; Gutschi M; Welzel J; Haas C
J Dtsch Dermatol Ges; 2014 Feb; 12(2):151-4. PubMed ID: 24238398
[No Abstract] [Full Text] [Related]
39. Current advances and perspectives in the treatment of advanced melanoma.
Livingstone E; Zimmer L; Vaubel J; Schadendorf D
J Dtsch Dermatol Ges; 2012 May; 10(5):319-25. PubMed ID: 22432863
[TBL] [Abstract][Full Text] [Related]
40. Histopathological features of cutaneous drug reactions to vemurafenib: a report of two cases.
Dabner M; Harvey NT; Soma A; Wood BA
Pathology; 2012 Dec; 44(7):661-4. PubMed ID: 23172086
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
